Navigation Links
Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia

GREENWOOD VILLAGE, Colo., July 5, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs") today announced treatment of the first patient in the three-arm, placebo controlled, 60 patient Phase 1b Ampion-In -Knee (AIK) trial in Australia. The active ingredient in Ampionhas extensive worldwide patent protection including composition of matter and use patents.  Anti-inflammatory and autoimmune modulation drugs constitute  one of the largest markets in the pharmaceutical industry.

About the Trial

  • This Phase 1b study is being conducted in patients diagnosed with a medical condition (pain and inflammation of the knee-osteoarthritis), which the study drug is intended to alleviate and confirm the hypothesis that the current outcome benefit is compatible with the mechanism of action of the drug.
  • In this study, Ampion™ (the low molecular fraction of commercial albumin preparation) is injected into the knees of patients with osteoarthritis of the knee in conjunction with standard therapy, including steroids, aiming to demonstrate a reduction in pain and improved range of motion compared to placebo.
  • The observation period in this study is short (72 hours) hence, results of this trial are anticipated to be available in the short term.

About Ampion

  • Ampion™ is a patented small molecule with non- steroidal anti-inflammatory and analgesic properties that is naturally produced by humans in response to injury. Because it is present in commercially available human serum albumin (which has been given to millions of people over several decades) it can be considered to be a biological.
  • Ampion may qualify as a new use for an existing drug with the potential of a shortened regulatory path compared to new drugs because human serum albumin is approved for intravenous administration to patients. For an informative Q & A about Ampion please click on

"We are all very excited that these significant human studies of Ampion are underway," stated Dr. David Bar-Or, founder and Chief Scientist. "We already understand a great deal about the mechanisms of action and potential usefulness of Ampion from our in-vitro studies using human tissue and in-vivo animal studies. There are hundreds of thousands of patients with painful conditions associated with inflammation that need new therapies and Ampion is a molecule produced by the body that appears to have a significant role in the homeostasis of inflammation.  Importantly, it may be used both acutely and chronically, orally, parenterally (by injection), topically or by inhalation. The human origin of Ampionsuggests the possible benefit of few side effects while providing effective relief for many patients whose pain and inflammatory condition is unabated by current medical treatments.

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website,

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, such as changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Relations
Ampio Pharmaceuticals, Inc.
After July 6 use: 720-437-6500

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
(Date:10/13/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... Therapy Catapult to advance development of large scale ... immunotherapy. Under the agreement, the Cell Therapy Catapult ... to support advanced clinical trials and eventual commercialization ... --> The Cell Therapy Catapult is a ...
(Date:10/12/2015)... WASHINGTON , Oct. 12, 2015  Former White House ... Press Secretary for the House Narcotics Committee, Robert Weiner ... "Rewriting Drug Policy." The two emphasize that this is now ... Clinton to Jeb Bush , Carly Fiorina ... Sordello cite the newest federal statistics, which they call "a ...
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... 2015, its guidance for the fourth quarter of 2015, ... Senior Secured Credit Facility. --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 , ... ... To incentivize would-be customers, eMarketing Concepts began a $1 promotion – effectively offering all ... a resounding success, and within weeks the company was flooded with phone calls from ...
(Date:10/13/2015)... ... , ... The Bill Howe Family of Companies is an award winning HVAC ... remediation services. Family-owned and operated for 35 years, they have maintained value, ethics and ... two years in a row from the Union Tribune Reader’s Poll, a Healthiest Company ...
(Date:10/12/2015)... ... 2015 , ... Heroes in Recovery (HIR) is proud to ... Network’s Moments of Change conference in West Palm Beach, Florida. Rob Waggener, CEO ... Dauphinais who exemplify the ideals of the Heroes in Recovery movement. , Noah ...
(Date:10/12/2015)... , ... October 12, 2015 , ... Kevin Costello, winner of the “Check-In and Win ... embarks today for his dream vacation to Hawaii. , “I didn’t believe I could win ... says. “This contest encouraged me to get to the gym and invest in my own ...
(Date:10/12/2015)... ... 12, 2015 , ... The American Society of Clinical Hypnosis ... education and clinical training in a health care discipline. , Many practitioners ... as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and ...
Breaking Medicine News(10 mins):